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Surgical approaches for lung volume reduction 
in emphysema
Lung volume reduction surgery (LVRS) for chronic obstructive 
pulmonary disease (COPD) is recommended in both British 
and international guidelines because trials have shown 
improvement in survival in selected patients with poor 
baseline exercise capacity and upper lobe-predominant 
emphysema. Despite this, few procedures are carried out, 
possibly because of historical concerns about high levels of 
morbidity and mortality associated with the operation. The 
authors reviewed data on lung volume reduction procedures 
at their institution between January 2000 and September 
2012. There were no deaths within 90 days of unilateral 
LVRS (n=81), bullectomy (n=20) or intracavity drainage 
procedures (n=14). These data suggest that concerns about 
surgical mortality should not discourage LVRS in selected 
patients with COPD, provided that it is undertaken within a 
multidisciplinary team environment involving appropriate 
patient selection.
KEYWORDS: Lung volume reduction surgery, emphysema,  under-
treatment, risk, mortality
Background
Chronic obstructive pulmonary disease (COPD) is a common 
and important condition responsible for considerable morbidity 
and mortality worldwide.1–5 Guidelines such as the recent national 
outcomes strategy for COPD,6 introduced in the British NHS, stress 
the importance of patients receiving appropriate care, and the use 
of surgical interventions in carefully selected patients is one element 
of this. Lung volume reduction surgery (LVRS) involves resecting 
the most emphysematous part of the lung to allow relatively 
healthier lung to be ventilated effectively. Operating lung volumes 
are reduced, which decreases the work of breathing and thus 
breathlessness. Data from the National Emphysema Treatment Trial 
(NETT) has shown that, in patients with upper lobe-predominant 
disease and a reduced exercise capacity, LVRS produces a clear 
and sustained survival benefi t as well as improvements in exercise 
capacity and quality of life.7 Therefore the COPD guidelines of the 
National Institute for Health and Care Excellence (NICE 2010) 
provide a grade A recommendation that patients with severe 
COPD who remain limited by breathlessness should be referred for 
consideration of LVRS.8
Although it is ‘known’ that LVRS improves outcomes in selected 
patients with emphysema,7–9 it appears that this knowledge is 
rarely acted on. Data from the UK Society of Cardiothoracic 
Surgery (SCTS) register (www.scts.org/professionals/audit_
outcomes.aspx) show that only 96 procedures in 2009–10 and 
90 in 2010–11 were recorded. The reasons for this are unclear 
but may be due to exaggerated concerns about the morbidity 
and mortality associated with the procedure. In the NETT study 
the mortality rate was 5.5% at 90 days post-surgery, and 24% of 
those undergoing surgery were still inpatients 30 days after the 
procedure. This is not just a UK issue; in the USA, in 2006, only 
105 Medicare benefi ciaries underwent LVRS.7 
The advanced COPD service at the Royal Brompton 
Hospital includes a multidisciplinary team (MDT) meeting 
at which patients with emphysema are discussed, involving 
a thoracic surgeon, respiratory physician and radiology, 
nursing and physiotherapy input. Conventional LVRS and 
bullectomy, as well as the Monaldi procedure which involves 
intracavity drainage of bullous lung disease combined 
with talc insuffl ation as a sclerosant, are considered.10 In 
addition, patients are assessed for possible participation in 
trials of experimental interventions such as bronchoscopic 
valve placement.11–14 This approach is intended to ensure 
appropriate patient selection, optimisation of patients 
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preoperatively, and a concentration of experience in this area 
to ensure that postoperative care is optimal. Decisions are 
based on factors including pulmonary function test results, 
the pattern of emphysema on thoracic computed tomography 
(CT), exercise capacity, the presence of signifi cant co-
morbidity and patient preference. 
Data on the morbidity and mortality associated with 
various surgical lung volume procedures should enable 
clinicians to have a clearer picture when considering them 
with their patients.
Methods
LVRS, bullectomy and the Monaldi procedures carried 
out between January 2000 and September 2012 were 
identifi ed from operating theatre records and hospital 
coding. Individual case records were then examined and 
data on survival, complications, and baseline and follow-up 
lung function collated. The primary outcome was 90-day 
mortality. The NETT classifi cation of surgical complications 
post-LVRS was used to allow like-for-like comparisons. 
Major pulmonary morbidity was defi ned as incidence of 
one or more of the following in the 30 days after LVRS: 
tracheostomy, failure to wean, pneumonia, and at least one 
postoperative intubation or ventilator use for 3 or more days. 
Major cardiac morbidity was defi ned as the incidence of one 
or more of the following: intraoperative or postoperative 
(in the 30 days after LVRS) arrhythmia requiring treatment, 
or myocardial infarction or pulmonary embolus in the 
30 days after LVRS.
Most LVRS procedures before 2003 were bilateral, whereas 
from 2003 (after a morbidity and mortality review) the 
standard approach in the authors’ institution became unilateral 
LVRS and the two outcomes were compared. Statistical analysis 
was performed using SPSS version 8. 
Results
A total of 144 procedures were identifi ed. The medical notes 
of six patients operated on in 2000–1 were unavailable 
(destroyed by water damage), leaving 138 procedures in 117 
patients (Fig 1). Mean (standard deviation [SD]) age was 
56.5 years (10 years), 78% were males with forced expiratory 
volume in 1 second (FEV1) of 36% (16.3%) predicted, carbon 
monoxide gas transfer factor (TLCO) was 42.2% (16.3%) 
predicted and residual volume:total lung capacity ratio 
0.59 (0.1). There were 104 LVRS procedures (81 unilateral, 
23 bilateral), 14 Monaldi procedures and 20 bullectomies. 
Further details of participant characteristics are broken down 
by procedure in Table 1. 
Mortality
The 90-day mortality rate for unilateral LVRS, bullectomy 
and intracavity drainage procedures was zero (confi dence 
interval [CI] 0–0.45% for unilateral LVRS). By contrast, for 
bilateral LVRS the 30-day mortality rate was 17.4% and the 
90-day mortality rate 21.7%, with the last death within 90 days 
occurring in 2003 when the switch to a unilateral approach 
occurred. 
Morbidity
At 30 days after the procedure, 6% of unilateral LVRS, 5% 
of bullectomy and 7% of Brompton procedure patients 
remained in hospital compared with 10% after a bilateral 
LVRS. Median length of stay was 14 days for bilateral LVRS 
and 10.5 days for unilateral LVRS. Major pulmonary or cardiac 
complications occurred in 39% and 13% of bilateral LVRS 
patients, respectively, compared with 11% and 6% for unilateral 
LVRS (Tables 2 and 3). This compares with rates of 29.8% for 
0 deaths within
90 days of
surgery
0 deaths within
90 days of
surgery
5 deaths within
90 days of
surgery
0 deaths within
90 days of
surgery
6 paents – medical
records destroyed
144 paents idenfied
138 procedures
on
117 paents
14 Monaldi
81 Unilateral 23 Bilateral
104 LVRS 20 Bullectomy
Fig 1. Numbers of patients undergoing lung 
volume reduction surgery procedures 
January 2000 to September 2012. 
LVRS = lung volume reduction surgery.
CMJ1402_Hopkinson.indd   123 3/13/14   7:55:12 PM
Samuel J Clark, Zaid Zoumot, Olivia Bamsey et al.
124 © Royal College of Physicians 2014. All rights reserved.
major pulmonary complications and 20% for major cardiac 
compilations in the NETT study.
Effi cacy
Improvements in lung function parameters were similar after 
unilateral and bilateral LVRS with a mean increase in FEV1 of 
32% (55%) for bilateral LVRS and 27% (37%) for unilateral 
(Table 4). Follow-up data for lung function was incomplete 
because some patients had been discharged back to local 
hospitals for followup.
Discussion
The main fi nding was that surgical lung volume reduction 
procedures currently in use, including unilateral LVRS, 
bullectomy and the Monaldi procedure, were associated with 
a zero 90-day surgical mortality, with much lower rates of 
morbidity with unilateral LVRS than reported previously with 
bilateral procedures in the NETT study.7 
Unilateral LVRS produced similar lung function 
improvements to the bilateral procedure. Although the authors 
have not undertaken a formal economic analysis, the value 
of the unilateral procedure is likely to be greater than that in 
the NETT study which investigated bilateral LVRS. First, the 
mortality and morbidity are lower. Second, the cost of the 
intervention is lower because hospital length of stay is shorter. 
Third, after bilateral LVRS patients would go to intensive 
care to recover initially, whereas after unilateral surgery they 
routinely receive level 2 care, which means that inpatient costs 
are lower. Currently, only bilateral LVRS is reimbursed in the 
USA but the present data suggest that this may be exposing 
patients to unnecessary risk, particularly where disease is very 
asymmetrical.
Given that LVRS is already recommended by NICE for 
selected patients with COPD,8 the small number of cases 
being performed in the UK and elsewhere is a concern because 
it means that some patients are missing out on an effective 
treatment. According to the UK Society for Cardiothoracic 
Surgery (SCTS) register, there were only 57 video-assisted 
thoracoscopic surgery (VATS) LVRS procedures and 39 open 
procedures in 2009–10. In 2010–11 there were 57 VATS and 33 
open procedures. Data on LVRS procedures were not recorded 
specifi cally for previous years. It is diffi cult to estimate the 
size of unmet need that this represents precisely, but it is likely 
to be large. Based on quality outcomes framework data from 
2012 (see www.gpcontract.co.uk) there are 1.1 million patients 
with COPD in the UK. Accurate data on the proportion of 
individuals with different disease severities are lacking, but, 
assuming that only 10% of these have severe or very severe 
disease and that of these 15% meet the criteria for LVRS (based 
on a US database study),17 this would still make approximately 
16,000 potentially eligible individuals. 
The authors speculate that low rates of LVRS may be because 
clinicians have an exaggerated impression of its morbidity and 
mortality based on NETT data or senior clinicians’ experience 
at the start of the century, before the high-risk cohort of people 
with an FEV1 and a TLCO <20% were identifi ed and excluded 
Table 1. Preoperative data for patients undergoing surgery for emphysema.∗
Data Bilateral LVRS 
(n=23)
Unilateral LVRS
(n=81)
Bullectomy 
(n=20)
Monaldi9
(n=14)
All patients
(n=138)
Age (years) 57.87 (5.23) 57.32 (10.1) 49.15 (12.1) 59.5 (8.0) 56.54 (10.0)
Males (%) 91.3 74.1 75 85.7 78.3
BMI (kg/m2) 23.96 (4.1) 23.8 (4.3) 24.6 (5.0) 23.4 (4.4) 23.9 (4.3)
Smoke exposure (pack-years) 42.1 (27.6) 39.4 (20.9) 32.6 (22.8) 52.3(36.0) 40.1 (24.2)
FEV1 (l) 0.80 (0.30) 1.12 (0.60) 1.63 (0.77) 1.05 (0.35) 1.14 (0.61)
FEV1 (% predicted) 25.9 (12.1) 35.8 (14.8) 51.4 (20.2) 32.5 (8.12) 36.0 (16.3)
FVC (l) 3.04 (0.65) 3.24 (0.94) 3.10 (0.92) 3.08 (1.11) 3.17 (0.91)
FVC (% predicted) 77.2 (18.1) 84.5 (19.4) 77.7 (20.9) 76.9 (23.7) 81.5 (20.0)
FEV1:FVC 25.0 (7.76) 32.8 (11.0) 52.0 (19.1) 33.1 (9.40) 34.01 (14.0)
RV (%) 263.5 (57.9) 216.9 (55.7) 188.3 (55.8) 223.2 (43.4) 221.7 (58.5)
TLC (% predicted) 138.4 (15.0) 127.7 (18.9) 109.7 (21.1) 125.7 (19.6) 126.9 (20.1)
RV:TLC 65.0 (7.86) 58.4 (10.5) 54.4 (10.1) 61 (10.4) 59.3 (10.4)
TLCO (% predicted) 40.5 (10.2) 39.8 (15.8) 55.0 (20.3) 42.1 (15.8) 42.2 (16.3)
PaO2 (kPa) 9.3 (1.3) 9.7 (1.2) 10.0 (1.1) 9.5 (0.8) 9.6 (1.2)
PaCO2 (kPa) 5.7 (1.2) 5.0 (0.5) 5.2 (0.6) 5.1 (0.5) 5.2 (0.7)
∗Values are mean (standard deviation).
BMI = body mass index; FEV1 = forced expiratory volume in 1 second; FVC = forced vital capacity; LVRS = lung volume reduction surgery; PaCO2 = partial pressure of 
carbon dioxide; PaO2 = partial pressure of oxygen; RV = residual volume; TLC = total lung capacity; TLCO = carbon monoxide gas transfer corrected for haemoglobin.
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Table 2. Outcomes of surgical groups at the Royal Brompton Hospital during the audit period.
Data Bilateral LVRS
(n=23) 
Unilateral LVRS
(n=81) 
Bullectomy 
(n=20)
Monaldi
(n=14)
All patients
(n=138)
Length of stay (days) 21.4 (24.1) 13.8 (11.0) 13.1 (21.2) 19.0 (19.9) 15.3 (16.2)
Returned to theatre (%) 30.4 12.2 10 0 13.8
Discharged with a chest drain (%) 31.6 16.5 10 7.7 16.8
Inpatient after 30 days (%) 10.5 6.2 5 7.1 6.7
Major cardiac complication (%)∗ 13 6.3 0 0 5.9
Major pulmonary complication (%)† 39.1 11.4 15 30.8 18.4
30-day mortality rate (%) 17.4 0 0 0 2.9
90-day mortality rate (%) 21.7 0 0 0 3.6
∗Major pulmonary morbidity is defined as incidence of one or more of the following in the 30 days after LVRS: tracheostomy, failure to wean, pneumonia, at least 
one postoperative intubation, or ventilator use for 3 or more days.
†Major cardiac morbidity is defined as incidence of one or more of the following: intraoperative or postoperative (in the 30 days after LVRS) arrhythmia requiring 
treatment or myocardial infarction or pulmonary embolus in the 30 days after LVRS.
LVRS = lung volume reduction surgery.
Table 3 Complications after LVRS – NETT (National Emphysema Treatment Trial) data vs Royal Brompton 
Hospital (RBH) experience.
Complication∗ NETT(n=511) RBH bilateral LVRS (n=23) RBH unilateral LVRS (n=79) 
None 41.3 30.4 29.6
Arrhythmia 23.5 13.0 6.3
Arrhythmia requiring treatment 18.6 13.0 6.3
Myocardial infarction 1.0 4.3 0
Failure of early extubation 3.9 30.4 3.8
Tracheostomy 8.2 8.7 1.3
Failure to wean 5.1 30.4 3.8
Reoperation for air leak 3.3 0 8.9
Pulmonary embolus 0.8 0 0
Readmission to ICU 11.7 17.4 6.3
Mediastinitis 0.6 0 0
Sternal debridement 0.6 4.3 0
Pneumonia 18.2 26.1 6.3
Urinary retention 3.5 0 2.5
Epidural catheter complications 0.8 4.3 0
Sepsis 2.5 17.4 2.5
Readmission within 72 hours after discharge 2.5 5.2 0
Ventilated >2 days 13.6 N/A N/A
Required reintubation 21.8 N/A N/A
Major pulmonary morbidity 29.8 39.1 11.4
Major cardiac morbidity 20 13 6.3
Died within 90 days of operation 5.5 21.7 0
∗All values are percentages.
The NETT study categorises both the intraoperative and the postoperative complications after lung volume reduction surgery (LVRS).15,16 The RBH audit used the 
same format to categorise surgical complications examining medical notes retrospectively. Two unilateral patients’ medical notes were unavailable and were not 
included in the audit of complications (although both were alive at 90 days).
LVRS = lung volume reduction surgery; N/A = not applicable; NETT = National Emphysema Treatment Trial; RBH = Royal Brompton Hospital.
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from the procedure. The current data show that this concern is 
indeed exaggerated. 
The second contributory factor may be the lack of 
standardised care pathways equivalent to those in place 
to ensure that patients with lung cancer are systematically 
considered for suitability for resection. The data on survival 
benefi t with LVRS in selected patients should mandate 
systematic assessment of patients to identify those with the 
appropriate characteristics – heterogeneous emphysema with 
a poor exercise capacity.7 In practice this approach should 
include routine assessment of pattern of emphysema by CT 
scan as well as gas transfer measurement in all patients with 
Medical Research Council (MRC) 4 or 5 dyspnoea and GOLD 
(Global Initiative for Chronic Obstructive Lung Disease) III or 
IV disease, unless there are obvious co-morbidities precluding 
surgery with review by an MDT, including chest physicians, 
surgeons and radiologists, as is already the case for the 
management of lung cancer. Many patients with COPD have a 
CT scan when admitted to hospital with an acute exacerbation 
to exclude other causes of breathlessness or chest discomfort, so 
systematic evaluation of these may be a good place to start. 
As well as the use of a unilateral approach, improvements in 
morbidity since the NETT study was published may also be 
due to improved surgical techniques and newer staple guns, 
which minimise leak, as well as improved aftercare including 
one-way chest drain valves that allow early discharge/shorter 
hospital stays.
Other lung volume reduction procedures are under 
development11–14 and there is emerging evidence that placement of 
endobronchial valves, where lobar exclusion can be achieved, may 
lead to a survival benefi t.18 The present data highlight that LVRS is 
the gold standard approach for lung volume reduction in patients 
with heterogeneous emphysema and that bronchoscopic therapies 
will need to prove their worth against it in terms of both effi cacy 
and safety. In addition, bronchoscopic approaches are likely to be 
more expensive than the UK LVRS tariff.
Low rates of referral for LVRS may be a manifestation of clinical 
nihilism. It remains conventional to write in reviews of COPD 
treatment that ‘only smoking cessation and oxygen in selected 
patients improve survival in COPD’. However, the present 
data should reinforce the benefi ts of LVRS, reassure clinicians 
of its safety in appropriately selected patients and support the 
development of a systematic, multidisciplinary approach to the 
management of patients with severe emphysema. ■
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